Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Patients Refractory to Conventional Therapy

Trial Profile

A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Patients Refractory to Conventional Therapy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SEL 212 (Primary) ; Pegloticase
  • Indications Gout; Gouty arthritis
  • Focus Therapeutic Use
  • Acronyms COMPARE
  • Sponsors Selecta Biosciences
  • Most Recent Events

    • 11 Nov 2019 Results presented in the Selecta Biosciences Media Release.
    • 08 Nov 2019 According to a Selecta Biosciences media release, the company expects to complete the enrollment of this study by the end of 2019. The company also expects to report interim data from the COMPARE trial in the first quarter of 2020, with top-line statistical superiority data expected by mid-2020.
    • 12 Jun 2019 Results published in the Selecta Biosciences media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top